涉及总金额11 8 4 . 9 9 亿元人民币。 作者 | 私募通 报道 | 决策投资圈 （ID： PEDATAMAX） 清科创业（0 1 9 4 5 .HK）旗下私募通统计：截至本周四下午，募资、投资、上市和并购共 1 3 9 起 事 件 ， 涉 及 总 金 额 1184.99 亿 人 民 币 。 从 交 易 金 额 来 看 ， 本 周 金 额 较 大 事 件 是 ： 2 0 25年3月3 1日，赛力斯集团股份有限公司成功受让华为技术有限公司持有的深圳引望 智能技术有限公司的10.0%的股权，作价11 5 . 0 0亿人民币。从交易事件地域分布看，目 前主要分布在广东省、江苏省和浙江省，占比为广东省16.7%，江苏省15.2%，浙江省 占13.6%。 更多信息请登录：h tt p s://ma x.pe da t a . c n/ 本周募资情况 本周新登记股权投资基金管理人共计4家，取消备案登记1家，全年截至目前累计股权投 资基金管理人数量为2 1家。本周新增备案基金数量为73只，规模总计936.86亿元，本周 备案基金募资最多的为国家军民融合产业投资基金二期有限责任公司，募集596.00亿人 民 币 。 ...

（ 转 载请注明出处：微信公众号 lixunlei0722 ） 关税加码背后的深层原因 年初至今，美国对他国的进口关税税率不断加码，尽管关税政策朝令夕改，但税率则超乎想象地往上加。如美方近日 公布的所谓"对等关税"方案，向所有贸易伙伴征收不同水平的关税，拟对中国加征 34% 关税，对欧盟、越南、中国 台湾地区、日本、印度、韩国、泰国、瑞士、印度尼西亚、马来西亚、柬埔寨等贸易伙伴征收 20% 到 49% 不等的 关税，对任何贸易伙伴的最低对等税率也为 10% 。 近年来中国对美顺差的占比已下降 来源： Wind ，中泰证券研究所 为此，我国也采取了向原产于美国的所有商品加征 34% 的进口关税，鉴于美方是在今年对中国加征 20% 关税基础 上再加征 34% 的，说明中方加征的关税属于克制的回应，且留有谈判余地。 特朗普再度当选总统之后，他的施政方略围绕着 MAGA ，即对外加征关税以获得 5000 亿美元以上的关税收入，又 能重振美国的制造业；对内通过政府效率部（ DOGE ）来精简机构、裁减公务员以节省开支、提高效率。同时，限制 移民、国内减税等政策可以起到鼓励投资、保护就业的作用。 特朗普任期与历任总统行政 ...

Group 1: MediaTek - MediaTek is expected to successfully transition from a traditional smartphone application processor supplier to a participant in the AI sector, starting with edge AI devices and expanding into AI-specific integrated circuits and smart automotive solutions [1] - Revenue and earnings CAGR is projected to reach 16% and 17% respectively from 2024 to 2027, with operating profit margin increasing from 19% in 2025 to 22% in 2027, driven by market share gains and demand for generative AI [1] Group 2: China Resources Land - China Resources Land is positioned for a recovery ahead of the industry due to lower debt and financing pressures, with contract sales growth expected to accelerate and market share in the primary housing market projected to increase by 2 percentage points to 5% by 2027 [2][17] - The average free cash flow yield from 2025 to 2027 is estimated at 11%, with an attractive valuation indicated by a price-to-book ratio of 0.4 for its development business [2][18] Group 3: Weichai Power - Weichai Power is anticipated to undergo a valuation reassessment due to improved cyclical prospects for heavy trucks and a more profitable engine product mix, with a projected P/E ratio of 10 times and a dividend yield of 6% by 2025 [3][8] - The company is expected to achieve a 18% CAGR in earnings per share over the next two years, supported by strong cash flow generation and increasing dividend payments [3][8] Group 4: Krafton - Krafton's strong performance in the PUBG series is identified as a key driver for profitability in 2025, overshadowing the early mixed feedback for the new game in development, inZoi [4] - The stock is currently trading near historical lows, with a projected P/E ratio of 12 times for 2025, indicating potential for market reassessment of its annual outlook [4]

Financial Data and Key Metrics Changes - The company is unable to provide detailed financial results due to the deconsolidation of Invizyne's financial statements, which has delayed the filing of the 10-K report [6][14][25] - As of December 31, the combination of cash and securities was $28 million, and Big Idea investments, represented by eXoZymes, was $64 million, totaling approximately $93 million [58] - The stock price as of December 31 was $6.30, with approximately 9.9 million shares outstanding, resulting in a market value of $62 million, indicating a negative market value of $30 million [58][59] Business Line Data and Key Metrics Changes - The company has successfully launched eXoZymes, marking a significant achievement despite challenging market conditions for small IPOs [14][15] - The shareholder count has increased by 12%, reaching approximately 1,800 shareholders [15] - The onboarding of investors through MDB Direct has begun, with over 500 accounts established by the end of the year [16] Market Data and Key Metrics Changes - There is a growing demand for microcap financing, with investors seeking liquid alternatives, positioning the company as a top curator of public venture opportunities [32] - The traditional venture capital and private equity markets are facing challenges, leading to increased interest from companies looking to go public [30][31] Company Strategy and Development Direction - The primary strategic priority is to expand the investor community, focusing on partnerships with RIAs and angel groups [35][41] - The company aims to transition from episodic deal-making to creating a consistent public venture asset class portfolio [34] - The company is optimistic about presenting new Big Idea investment opportunities in the near future, with a focus on companies that are more developed and potentially have revenue [80] Management's Comments on Operating Environment and Future Outlook - Management is excited about the significant increase in opportunities being presented, both from community members and through their own curation efforts [26][27] - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] - The company is focused on maintaining operational efficiencies and reducing cash operational expenses while increasing revenue from various lines [62] Other Important Information - The company has licensed new assets from Mayo Clinic and is developing that opportunity, with plans for potential further investment [49][50] - The company continues to work with HeartBeam, which is developing groundbreaking technology for self-administered ECGs, with significant market potential [44] Q&A Session Summary Question: Does Lou Basenese still work for the organization? - Lou Basenese has left the company but remains a friend and supporter, focusing on his media presence [65][66] Question: What does the deconsolidation mean for MDB stockholders and eXoZymes' investors? - The deconsolidation will clarify the financials of MDB, separating its performance from eXoZymes, making it easier to understand [70][71] Question: How many Big Idea companies are expected to be established in 2025? - The company anticipates presenting three to four new Big Ideas this year, with some being more developed and potentially having revenue [80][81] Question: How do you see the regulatory winds changing? - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] Question: When do you expect to make any type of dividend? - The company aims to see a value-creating event within eXoZymes before considering any distributions to shareholders [92][93] Question: How should shareholders think about the investment in cash and resources relative to value creation? - The company intends to maintain a modest amount of cash for new opportunities while leveraging existing investments to create value [99][100]

将投中网设为"星标⭐"，第一时间收获最新推送 速览投资风口，掌握资本律动。 作者丨簪竹 业投资基金共同投资。 此外，瑞桥鼎科集团宣布完成A轮融资，融资金额超过十亿元人民币。本轮 融资由康桥资本领投，北京市医药健康产业投资基金、北商资本跟投。 据投中网不完全统计，投融资详情如下（统计周期03月22日—03月28日）： 新消费 洛梵狄完成近1亿元融资 3月25日消息，智能短途出行核心零部件供应商洛梵狄智能科技（简称：洛梵狄）完成近1亿元B轮 融资，投资方有广州产投、迪策投资（湖南省钢铁集团下属投资平台）和达晨财智。 禧点茶韵完成3000万元A轮融资 来源丨投中网 大家好，我是长风。今天给大家带来上周资本市场的专业投研信息。 上周焦点回顾： 低空经济赛道，两家低空企业有钱了。 3月27日，时的科技宣布完成B+轮战略融资，本轮融资由上 海大零号湾创投和紫峰资本联合投资。同一天，翊飞航空科技也宣布完成亿元级别融资，本轮融资由 普华资本领投。 硬科技赛道，启明连投两家机器人。 3月26日消息，具身智能初创公司它石智航（TARS）宣布完成 天使轮1.2亿美元融资。本轮融资由蓝驰创投、启明创投共同领投，线性资本、恒旭资本、洪 ...

Core Insights - The article discusses the recent policy changes by the China Securities Regulatory Commission (CSRC) that facilitate Chinese companies' listings in the U.S., creating a "fast track" for international financing opportunities [1][2]. Policy Updates - On March 11, the CSRC announced three major breakthroughs aimed at addressing long-standing challenges for companies seeking to list abroad, thereby easing the international financing process for high-quality enterprises [2]. - The CSRC has established a "red/yellow/green" channel system based on industry characteristics, company qualifications, and risk levels. The green channel is for innovative tech companies with good compliance records, allowing for expedited review processes [3]. - The yellow channel targets companies with minor compliance issues but solid business fundamentals, while the red channel is for firms with sensitive data or special regulatory requirements, necessitating multi-department reviews [4]. Efficiency Improvements - The automatic extraction of key data from prospectuses has increased risk identification accuracy to 92% [5]. - Eight departments, including foreign exchange management and data security, have implemented a "one-stop service" for processing applications [5]. - A regular communication mechanism with the Public Company Accounting Oversight Board (PCAOB) has been established, tripling the efficiency of resolving audit disputes [5]. New Financing Landscape - High-quality Chinese companies are now allowed to initiate small-scale quarterly offerings, exempting certain reviews if the financing does not exceed 5% of their market value [6]. - Clear exit pathways for private equity and venture capital investors have been defined, along with dedicated channels for sovereign funds and ESG investors [6]. - A pilot program for a dual-counter mechanism between Hong Kong and U.S. markets has been launched, unlocking over 200 billion offshore RMB funds [7]. Nasdaq Listing Advantages - Companies listing on Nasdaq not only gain financing but also enhance their international visibility, facilitating domestic and international collaborations [11]. - Nasdaq offers a range of value-added services, with no time restrictions on subsequent financing, allowing for rapid follow-on offerings within six months [11]. - As of May 13, 2024, there are 16,786 companies listed in the U.S. with a total market capitalization of $59 trillion [14]. Market Statistics - As of May 10, 2024, 162 Chinese companies are listed in the U.S., with a total market value of $1.743646 trillion. Among these, 133 are on Nasdaq and 29 on the New York Stock Exchange [15].

Summary of BeiGene Conference Call Company Overview - **Company**: BeiGene - **Industry**: Biotechnology, specifically focused on oncology Key Points and Arguments - **Market Position**: BeiGene is a leading player in the Chinese biotechnology industry, with strong global R&D, production, and commercialization capabilities. The year 2025 is pivotal, with expectations of profitability driven by the expansion of the BTK inhibitor, Zanubrutinib, in overseas markets. Revenue growth is projected at 21%, reaching $6.7 billion by 2027, with profits exceeding $800 million [3][4][29]. - **Product Pipeline**: BeiGene has a comprehensive pipeline in oncology, particularly in hematological malignancies, covering treatment scenarios from initial to relapsed and refractory stages with BTK inhibitors, BCL-2 inhibitors, and BTK-C degradation agents [4][5]. - **Zanubrutinib Performance**: Zanubrutinib has outperformed ibrutinib in head-to-head clinical trials, becoming the preferred therapy for C11 indications. It is expected to generate $2.6 billion in total revenue by 2024, with $2 billion from the U.S. market, marking a year-on-year doubling [4][15][17]. - **BCL-2 Inhibitor Development**: BeiGene is advancing its BCL-2 inhibitor in clinical trials, aiming to challenge existing competitors with fixed therapy approaches. A Phase III trial for chronic lymphocytic leukemia (CLL) is expected to complete enrollment in 2025, with a U.S. market launch anticipated by 2027 [4][18]. - **PD-1 Drug Commercialization**: The PD-1 drug, BaiZeAn, has been approved for 14 indications, with 13 covered by insurance in China. The domestic market is nearing saturation, while overseas markets are expected to contribute $500 million to $1 billion in growth, with peak sales potentially reaching $1 billion [4][23]. - **Breast Cancer Focus**: BeiGene is focusing on CDK4 inhibitors in breast cancer to address toxicity and resistance issues associated with existing CDK46 inhibitors. Early data shows promise, with positive proof of concept (POC) data expected in the first half of 2025 [4][24]. - **Risks**: Key risks include market competition for Zanubrutinib, price reduction risks from the U.S. IRA Act, uncertainties surrounding early clinical products, and potential impacts from biopharmaceutical procurement and insurance policies [4][30]. Additional Important Content - **Stock Performance**: From 2019 to 2021, BeiGene's stock price surged post-product launches. However, from 2022 to 2023, the stock faced pressure due to market conditions. Positive data releases for Zanubrutinib have significantly boosted stock performance [6]. - **Commercialization Team**: BeiGene has a global clinical team of 3,000 and a commercialization team of over 500 in the U.S. and Europe, enabling efficient multi-center clinical trials and substantial sales of nearly $2 billion in molecular drugs [9]. - **Future Growth Projections**: Revenue is expected to grow to $5 billion in 2025, $6 billion in 2026, and $6.7 billion in 2027, with a projected net profit exceeding $800 million by 2027 [29]. - **Valuation Estimates**: Based on management guidance, BeiGene's market value is estimated to reach $30 billion, driven by peak sales of its key products [28]. - **Emerging Competitors**: Several companies are developing BCL-2 targeted drugs, with BeiGene positioned in the leading tier, expecting to read out Phase III data in 2026 [19]. This summary encapsulates the critical insights from the conference call, highlighting BeiGene's strategic positioning, product pipeline, market dynamics, and potential risks.

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The "America First Investment Policy" aims to maintain a strong and open investment environment in the U.S. while protecting against potential threats from foreign investments [1] - The policy encourages investments from allied and partner countries, particularly in emerging technologies like artificial intelligence [2] - There is a significant focus on limiting investments from foreign adversaries, especially in critical sectors such as technology, healthcare, and energy [3][6] - The memorandum indicates a strategic shift in U.S. investment policy, particularly targeting China, with an emphasis on economic security as a component of national security [8] Summary by Sections Section: Policy Overview - The memorandum establishes a "fast track" procedure for investments from specific allied nations in advanced technology sectors [2] - It mandates environmental reviews for investments exceeding $1 billion in the U.S. [2] Section: Restrictions on Foreign Investments - The policy will utilize legal means to restrict foreign adversaries from investing in sensitive U.S. technologies and infrastructure [3] - It aims to prevent U.S. investments in sectors that support China's military-civil fusion strategy [6] Section: Implications for U.S.-China Relations - The memorandum suggests that future Chinese investments in the U.S. may face stricter scrutiny, particularly in key technology areas [8] - The report anticipates limited short-term economic impact but highlights the ongoing strategic competition between the U.S. and China in advanced manufacturing and AI [10] Section: Market Reactions - The report notes a trend of capital shifting away from sensitive technology sectors towards non-sensitive areas like consumer services and commercial real estate [10] - It emphasizes the need to monitor changes in foreign capital flows in the secondary market due to the policy's implications [10]

《2025年国务院政府工作报告》（简称"政府工作报告"）出炉，明确2025年发展蓝图。 政府工作报告提到，要"因地制宜发展新质生产力，加快建设现代化产业体系"，要"培育壮大新兴产业、未来产业""推动传统产业改造提升""激发数字经济创 新活力"。在需求侧，要"大力提振消费、提高投资效益，全方位扩大国内需求""推动更多资金资源'投资于人'、服务于民生"。 上市公司是新质生产力发展和服务民生的重要微观主体，记者了解到，政府工作报告提出的关于发展新质生产力、推进高水平科技自立自强等内容引起沪市 代表委员的广泛关注。 发挥科技领军企业龙头作用 政府工作报告提出，"推进高水平科技自立自强。充分发挥新型举国体制优势，强化关键核心技术攻关和前沿性、颠覆性技术研发，加快组织实施和超前布局 重大科技项目""发挥科技领军企业龙头作用，加强企业主导的产学研深度融合，从制度上保障企业参与国家科技创新决策、承担重大科技项目""健全创投基 金差异化监管制度，强化政策性金融支持，加快发展创业投资、壮大耐心资本"等。 在推进高水平科技自立自强的进程中，上市公司扮演着科技创新主力军的作用。近年来，上市公司通过主导产学研融合、承担重大科技项目等方 ...

本周募资情况 本周新登记股权投资基金管理人共计0家，取消备案登记3家，全年截至目前累计股权投 资基金管理人数量为11家。本周新增备案基金数量为 81只 ，规模总计 535.04亿元 ，本周备案基金募资最多的为北京经济技术开发区政府投资引导基金二期（有限合 伙），募集100.00亿人民币。全年截至目前累计股权投资备案基金数量为631只，规模 总计5558.75亿元。（2025年2月21日-2025年2月27日） 新备案基金地域分布TOP5 涉及总金额693.36亿元人民币。 作者 | 私募通 来源 | 决策投资圈 （ID：PEDATAMAX） 清科创业（01945.HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购 共 165起 事件，涉及总金额 693.36亿 人民币。从交易金额来看，本周金额较大事件 是：2025年2月25日，奉新时代新能源材料有限公司、江西飞宇新能源科技有限公司对 宜春盛源锂业有限责任公司进行增资，出资金额是26.00亿人民币。从交易事件地域分 布看，目前主要分布在广东省、江苏省和北京市，占比为广东省19.1%，江苏省 14.3%，北京市13.1%。 01 02 本周投资情况 清 ...